|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM165179570 |
| 003 |
DE-627 |
| 005 |
20231223104146.0 |
| 007 |
tu |
| 008 |
231223s2006 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0551.xml
|
| 035 |
|
|
|a (DE-627)NLM165179570
|
| 035 |
|
|
|a (NLM)16952484
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Castro-Santos, Patricia
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a TNFalpha genotype influences development of IgA-ASCA antibodies in Crohn's disease patients with CARD15 wild type
|
| 264 |
|
1 |
|c 2006
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 05.01.2007
|
| 500 |
|
|
|a Date Revised 19.11.2015
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a A typical feature of Crohn's disease (CD) patients is the development of antibodies against self- (PAB) or exogenous (ASCA) antigens, a process in which mucosal cytokine expression pattern might be involved. On the other hand, mutations in CARD15, a genetic risk factor for CD, alter cytokine production in response to bacterial infection. In the present study, we evaluated the role of functionally relevant IL-10 and TNFalpha gene polymorphisms in the synthesis of these antibodies and their relationship with CARD15 mutations. In CARD15 wild type patients, high TNFalpha producer genotypes protect against IgA-ASCA development, whereas an inverse association was observed in autoantibody synthesis (PAB). These associations were not observed in patients with CARD15 mutations, probably due to the lack of TNFalpha release as a consequence of the failure of CARD15 protein to recognize the peptidoglycan. Thus, we proposed a CARD15-TNFalpha circuit that might play a role in mucosal immune surveillance
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Antibodies, Fungal
|2 NLM
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin A
|2 NLM
|
| 650 |
|
7 |
|a NOD2 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Nod2 Signaling Adaptor Protein
|2 NLM
|
| 650 |
|
7 |
|a Tumor Necrosis Factor-alpha
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-10
|2 NLM
|
| 650 |
|
7 |
|a 130068-27-8
|2 NLM
|
| 700 |
1 |
|
|a Mozo, Lourdes
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gutiérrez, Carmen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Suárez, Ana
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 121(2006), 3 vom: 30. Dez., Seite 305-13
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:121
|g year:2006
|g number:3
|g day:30
|g month:12
|g pages:305-13
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 121
|j 2006
|e 3
|b 30
|c 12
|h 305-13
|